Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03023631 · ClinicalTrials.gov registry record · Phase 4

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

A Phase 4 study of Hematopoietic and Lymphoid Cell Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 4
Development phase
48
Enrollment target
1
Study location

NCT03023631 is a Phase 4 study of Hematopoietic and Lymphoid Cell Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants, below the 952-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03023631, a Phase 4 study of Hematopoietic and Lymphoid Cell Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant. Vaccines, such as Gardasil 9, may help the body build an effective immune response to kill cancer cells.

Conditions Studied

Hematopoietic and Lymphoid Cell Neoplasm Allogeneic Hematopoietic Stem Cell Transplant Recipient

Interventions

  • BIOLOGICAL Recombinant Human Papillomavirus Nonavalent Vaccine

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2017-04-23
Est. Completion 2026-07-31
Phase Phase 4

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03023631

The ClinicalTrials.gov registry entry for NCT03023631 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (95% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Recombinant Human Papillomavirus Nonavalent Vaccine is the first listed.

NCT03023631 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03023631 about?

NCT03023631 is a clinical study titled "Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant". This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant. Vaccines, such as Gardasil 9, may help the body build an effective immune response to kill cancer ...

What is the current status of trial NCT03023631?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2017-04-23. Estimated completion is 2026-07-31.

What conditions does trial NCT03023631 study?

This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Allogeneic Hematopoietic Stem Cell Transplant Recipient.

What interventions are being tested in trial NCT03023631?

The interventions under investigation include: Recombinant Human Papillomavirus Nonavalent Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT03023631?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03023631 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hematopoietic and Lymphoid Cell Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hematopoietic and Lymphoid Cell Neoplasm

All registered trials for this condition

Allogeneic Hematopoietic Stem Cell Transplant Recipient

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.